MaxCyte, Inc. Grant of Options (6906L)

TIDMMXCT TIDMMXCR

RNS Number : 6906L

MaxCyte, Inc.

20 July 2017

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options

Maryland, USA - 20 July 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialisation of next-generation, cell-based medicines, announces that it has granted, effective July 14, 2017, a total of 686,400 options of common stock in the Company ("Common Stock") to PDMRs who are directors or officers of the Company ("Option Grants"). Details of the Option Grants are given below:

 
 Option Grants 
  to PDMRs 
--------------------  -------- 
 Doerfler, Doug        296,000 
--------------------  -------- 
 Holtz, Ron            134,800 
--------------------  -------- 
 Madhusudan, Peshwa    136,100 
--------------------  -------- 
 Thompson, J. Stark     23,900 
--------------------  -------- 
 Mandell, Art           23,900 
--------------------  -------- 
 Erck, Stan             23,900 
--------------------  -------- 
 Brooke, Will           23,900 
--------------------  -------- 
 Johnston, John         23,900 
--------------------  -------- 
 Total                 686,400 
--------------------  -------- 
 

Options Grants to PDMRs vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on July 14, 2017, of 242.50 pence.

About MaxCyte

MaxCyte (LSE: MXCT, MXCR) is a US-based global company dedicated to driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology. With its robust delivery platform, MaxCyte's team of scientific experts helps its partners to unlock their product potential and solve problems. This platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large-scale, clinical and commercial grade cell engineering in a non-viral system and with low-toxicity concerns. The Company's cell-engineering platform is FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path to commercialize cell-based medicines. MaxCyte is also developing CARMA, its proprietary, breakthrough platform in immuno-oncology, to rapidly manufacture CAR therapies for a broad range of cancer indications, including solid tumors where existing CAR-T approaches face

significant challenges.   For more information, visit http://www.maxcyte.com/ 

###

 
   MaxCyte Inc. 
    Doug Doerfler, Chief Executive 
     Officer 
     Ron Holtz, Chief Financial 
     Officer                               [phone] 
 
     Nominated Adviser and Broker 
     Panmure Gordon 
    Freddy Crossley (Corporate 
     Finance) 
     Duncan Monteith 
     Ryan McCarthy 
     Tom Salvesen (Corporate Broking)      [phone] 
 
     Financial PR Adviser 
     Consilium Strategic Communications 
    Mary-Jane Elliott                      [phone] 
     Chris Welsh                            [e-mail] 
     Lindsey Neville 
 
 
  1   Details of the person discharging managerial 
       responsibilities / person closely associated 
---  --------------------------------------------------------------- 
 a)   Names                    Doerfler, Doug 
                                Holtz, Ron 
                                Madhusudan, Peshwa 
                                Thompson, J. Stark 
                                Mandell, Art 
                                Erck, Stan 
                                Brooke, Will 
                                Johnston, John 
---  -----------------------  -------------------------------------- 
 2    Reason for the notification 
---  --------------------------------------------------------------- 
 a)   Position/status          Doerfler, Doug - CEO and Director 
                                Holtz, Ron - CFO and Director 
                                Madhusudan, Peshwa - CSO 
                                Thompson, J. Stark - Non-executive 
                                Chairman 
                                Mandell, Art - Non-executive 
                                Director 
                                Erck, Stan - Non-executive Director 
                                Brooke, Will - Non-executive 
                                Director 
                                Johnston, John - Non-executive 
                                Director 
---  -----------------------  -------------------------------------- 
 b)   Initial notification     Initial Notification 
       /Amendment 
---  -----------------------  -------------------------------------- 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
---  --------------------------------------------------------------- 
 a)   Name                     MaxCyte, Inc. 
---  -----------------------  -------------------------------------- 
 b)   LEI                      54930053YHXULRFCU991 
---  -----------------------  -------------------------------------- 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; 
       and (iv) each place where transactions have 
       been conducted 
---  --------------------------------------------------------------- 
 a)   Description              Grant of Options over Shares 
       of the financial         of Common Stock 
       instrument, 
       type of instrument 
---  -----------------------  -------------------------------------- 
 b)   Identification           US57777K1060 
       code 
---  -----------------------  -------------------------------------- 
 c)   Nature of the 
       transactions              Grant of Options to PDMRs 
---  -----------------------  -------------------------------------- 
 d)   Price(s) and             Doerfler, Doug - 296,000 at an 
       volume(s)                exercise price of 242.50 pence 
                                Holtz, Ron - 134,800 at an exercise 
                                price of 242.50 pence 
                                Madhusudan, Peshwa - 136,100 
                                at an exercise price of 242.50 
                                pence 
                                Thompson, J. Stark - 23,900 at 
                                an exercise price of 242.50 pence 
                                Mandell, Art - 23,900 at an exercise 
                                price of 242.50 pence 
                                Erck, Stan - 23,900 at an exercise 
                                price of 242.50 pence 
                                Brooke, Will - 23,900 at an exercise 
                                price of 242.50 pence 
                                Johnston, John - 23,900 at an 
                                exercise price of 242.50 pence 
---  -----------------------  -------------------------------------- 
 d)   Aggregated information    n/a 
       - Aggregated 
       volume 
       - Price 
---  -----------------------  -------------------------------------- 
 e)   Date of the              14 July 2017 
       transactions 
---  -----------------------  -------------------------------------- 
 f)   Place of the             Outside a trading venue 
       transaction 
---  -----------------------  -------------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEAXXEAEEXEFF

(END) Dow Jones Newswires

July 20, 2017 13:02 ET (17:02 GMT)